TORONTO, March 31, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation.
Press Releases
Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “Lung Endothelial Binding Agents And Methods Of Use” to protect new drug candidates that reduce lung inflammation.
Arch Biopartners Safely Completes Expanded Dosing of METABLOK in Phase I Human Trial and Begins Focus on Phase II Trial
TORONTO, March 17, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final eight healthy volunteers in its Phase I human trial of Metablok (LSALT peptide). This final group received the highest daily dose of Metablok tested to date for three consecutive days and met the primary endpoints of safety and tolerability.
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok (LSALT peptide) for future Phase II trials targeting inflammation in the lung, the kidney and/or the liver by adding a cohort of eight healthy volunteers to receive the highest daily dose tested to date for three consecutive days.
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0
TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Dr. Daniel Hassett’s team at the University of Cincinnati (UC) College of Medicine, and its collaborators, have published details regarding the efficacy of AB569 in killing various multidrug resistant bacteria.
Arch Biopartners Closes Convertible Note Financing
TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000 (the “Offering”).
The Note matures on February 1, 2025 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $0.89, in the thirty-day period prior to the maturity of the Note.
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide) has completed dosing of all scheduled volunteers and Metablok has met the primary endpoints of safety and tolerability. Metablok is the Company’s lead drug candidate for treating organ damage caused by inflammation.
Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury
TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today the U.S. Patent and Trademark Office (USPTO) has issued to Arch U.S. Patent number 10,493,127 titled, “Dipeptidase-1 Binding Compositions and Methods of Treatment”.
Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide), the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers.
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr. Stephen Robbins and Dr. Paul Kubes at the University of Calgary, and their collaborators, have published a paper in the journal Cell describing a novel mechanism action for inflammation mediated organ injury involving the recruitment of white blood cells (neutrophils) from the bloodstream into injured or infected organ tissues.